ClinicalTrials.gg
RecruitingNCT03206099Updated Nov 17, 2026

NIAID Centralized Sequencing Protocol

An observational study in Atopy, Primary Immunodeficiency and Autoimmunity, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 2 sites in United States. Open to participants aged 1 Day to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational

How we know

From the registry’s dates

  • Started Jul 2017; still recruiting 9 years 3 months later.
Updated Oct 26, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
20,000
Ages
1 Day to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID) — 11 open to participants now, 11 under way, none of them phase 3. Primary Immunodeficiency Diseases · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
Largest of 11
20,000 · median 1,190
Started
2017
with 1 other
Observational
11 of 16
10 open now
Registered
10th of 16
by date

Among the 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID), this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2017, is one of 11 observational ones, and was the 10th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

11 of the 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 1 Day to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

Background:

Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems.

Objective:

To understand the genetics of immune disorders various health conditions, as well as outcomes of clinical genomics and genetic counseling services performed under this protocol.

Eligibility:

Participants in other NIH human subjects research protocols - either at the NIH Clinical Center (CC) or at Children's National Health System (CNHS) - (aged 0-99 years), and, in select cases, their biological relatives

Design:

Researchers will study participant's DNA extracted from blood, saliva, or another tissue sample, including previously collected samples we may have stored at the NIH. Researchers will look at participant's DNA in great detail. We are looking for differences in the DNA sequence or structure between participants and other people.

Participants will receive results that:

  • Are important to their health
  • Have been confirmed in a clinical lab
  • Suggest that they could be at risk for serious disease that may affect your current or future medical management.

Some genetic information we return to participants may be of uncertain importance.

If genetic test results are unrelated to the participant's NIH evaluations, then we will not typically report:

  • Normal variants
  • Information about progressive, fatal conditions that have no effective treatment
  • Carrier status (conditions you don t have but could pass on)

The samples and data will be saved for future research.

Personal data will be kept as private as possible.

If future studies need new information, participants may be contacted.

Read the detailed description

Investigators at the National Institute of Allergy and Infectious Diseases (NIAID) use next-generation sequencing technologies to help determine genetic contributions to immune diseases. These efforts have increased rates of molecular diagnosis for a subset of NIAID

participants as well as uncovered fundamental insights into the cellular and signaling pathways in host defense and immune regulation.

Despite these successes, analysis and interpretation of genomic data remain a substantial challenge. Simply, researchers do not understand the functional and clinical consequences of most human genetic variation. This is true at NIAID and across the intramural research program. Making progress in this area requires a coordinated, systematic, and transparent approach to clinical genomics research.

This protocol is specific to genetic testing and explicitly aims to both strengthen clinical care and enhance research throughout participating programs at the NIH. Probands will provide biological specimens for genetic testing and will be required to be enrolled on a primary protocol, which will execute the primary clinical and research evaluations. This protocol serves as a vehicle for a

programmatic effort that includes standardized phenotyping, test ordering through the Clinical Research Information System (CRIS), sample collection and isolation, nucleic acid analysis, bioinformatics, clinical interpretation, reporting in CRIS, genetic counseling, and supporting effective use of genomics as a research tool throughout the intramural program. Genetic testing results and data (upon request) will be shared with the research teams for protocols on which a given participant is co-enrolled. Overall, increased process standardization will support data integrity and efficiency while still accommodating the need for investigator flexibility.

03

Conditions studied

  • Atopy
  • Primary Immunodeficiency
  • Autoimmunity
  • Autoinflammation

Keywords

  • Phenotyping
  • Genetics
  • Sequencing
  • Inborn Errors of Immunity
  • Genomics
  • Natural History
04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
1 Day to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Probands and their biological relatives (primarily clinical), recruited from NIAID protocols (both at the NIH and CNHS).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must fulfill one of the following criteria:

    • Proband participants: must be individuals under investigation by another NIH protocol on which they are co-enrolled, or are referred from the GDMCC protocol "Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults" (NCT04702243) or "Use of Tiered Genetic Sequencing and Specialty Referral for Identifying and Managing Rare Genetic Causes of Chronic Suppurative Respiratory Disease" (External study #: 26-1761). Probands may have a disease under investigation or be healthy volunteers.
    • Biological relatives: biologically related to a proband participant.
  • Aged 0-99 years.
  • Participants must be willing to undergo genetic testing.
  • Participants must be willing to allow samples to be stored for future research.
  • Participants must be willing to have their de-identified genomic data shared, for example in a controlled access databases like the Database of Genotypes and Phenotypes (dbGaP).
  • To complete surveys and interviews:

    • Proficient with the English language.
    • Able to provide .
  • Adult healthy volunteers must be able to provide informed consent.

Exclusion criteria

EXCLUSION CRITERIA:

Any condition that, in the opinion of the investigator, contraindicates participation in this study is a reason for exclusion.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
20,000 participants (estimated)

Groups and cohorts

  • Biological relatives

    Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.

  • Healthy volunteers

    Select internal controls

  • Probands

    Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.

06

What researchers measure

Primary outcomes

  1. Identifying novel genetic defects associated with immune disorders

    Identifying novel genetic defects associated with immune disorders

    Time frame: Upon analysis of genomic data

  2. Identifying novel clinical phenotypes associated with established genetic defects

    Identifying novel clinical phenotypes associated with established genetic defects

    Time frame: Upon analysis of genomic data

  3. Identifying established genetic disorders of the immune system

    Identifying established genetic disorders of the immune system, as well as known genetic disorders outside of the immune system in some cases

    Time frame: Upon analysis of genomic data

Secondary outcomes

  1. Evidence base for how to improve clinical genomic services on this protocol and related programs.

    Studies of the processes and outcomes of the clinical genomics and genetic counseling services performed under this protocol. These studies will use surveys, interviews, and other social and behavioral research methods to collect data from study participants about their perceptions, experiences, and attitudes related to their condition and participation in this protocol. The goal of these additional studies will be to improve the services provided under protocol 17-I-0122 and to generate an evidence base for other investigators conducting similar studies.

    Time frame: 5.1.1. Enrollment/Baseline Report Comprehension Survey and Semi-Structured Phone Interviews

07

Study locations

2 of 2 sites recruiting
  • Children's National Health System
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Publications

  • Zainab R, Kaur S, Lack J, Similuk M, Tandon M, Ghosh R, Seifert BA, Tokita M, Flippo C, Yan J, Walkiewicz M, Chittiboina P, Tatsi C. Genetic evaluation of pediatric pituitary adenomas and USP8-related genotype-phenotype correlations in Cushing's disease. Pituitary. 2025 Aug 14;28(5):92. doi: 10.1007/s11102-025-01557-6. PubMed 40813536 ↗
  • Beers BJ, Similuk MN, Ghosh R, Seifert BA, Jamal L, Kamen M, Setzer MR, Jodarski C, Duncan R, Hunt D, Mixer M, Cao W, Bi W, Veltri D, Karlins E, Zhang L, Li Z, Oler AJ, Jevtich K, Yu Y, Hullfish H, Bielekova B, Frischmeyer-Guerrerio P, Dang Do A, Huryn LA, Olivier KN, Su HC, Lyons JJ, Zerbe CS, Rao VK, Keller MD, Freeman AF, Holland SM, Franco LM, Walkiewicz MA, Yan J. Chromosomal microarray analysis supplements exome sequencing to diagnose children with suspected inborn errors of immunity. Front Immunol. 2023 May 5;14:1172004. doi: 10.3389/fimmu.2023.1172004. eCollection 2023. PubMed 37215141 ↗
  • Ferre EMN, Yu Y, Oikonomou V, Hilfanova A, Lee CR, Rosen LB, Burbelo PD, Vazquez SE, Anderson MS, Barocha A, Heller T, Soldatos A, Holland SM, Walkiewicz MA, Lionakis MS. Case report: Discovery of a de novo FAM111B pathogenic variant in a patient with an APECED-like clinical phenotype. Front Immunol. 2023 Feb 17;14:1133387. doi: 10.3389/fimmu.2023.1133387. eCollection 2023. PubMed 36875114 ↗
  • Similuk MN, Yan J, Ghosh R, Oler AJ, Franco LM, Setzer MR, Kamen M, Jodarski C, DiMaggio T, Davis J, Gore R, Jamal L, Borges A, Gentile N, Niemela J, Lowe C, Jevtich K, Yu Y, Hullfish H, Hsu AP, Hong C, Littel P, Seifert BA, Milner J, Johnston JJ, Cheng X, Li Z, Veltri D, Huang K, Kaladi K, Barnett J, Zhang L, Vlasenko N, Fan Y, Karlins E, Ganakammal SR, Gilmore R, Tran E, Yun A, Mackey J, Yazhuk S, Lack J, Kuram V, Cao W, Huse S, Frank K, Fahle G, Rosenzweig S, Su Y, Hwang S, Bi W, Bennett J, Myles IA, De Ravin SS, Fuss I, Strober W, Bielekova B, Almeida de Jesus A, Goldbach-Mansky R, Williamson P, Kumar K, Dempsy C, Frischmeyer-Guerrerio P, Fisch R, Bolan H, Metcalfe DD, Komarow H, Carter M, Druey KM, Sereti I, Dropulic L, Klion AD, Khoury P, O' Connell EM, Holland-Thomas NC, Brown T, McDermott DH, Murphy PM, Bundy V, Keller MD, Peng C, Kim H, Norman S, Delmonte OM, Kang E, Su HC, Malech H, Freeman A, Zerbe C, Uzel G, Bergerson JRE, Rao VK, Olivier KN, Lyons JJ, Lisco A, Cohen JI, Lionakis MS, Biesecker LG, Xirasagar S, Notarangelo LD, Holland SM, Walkiewicz MA. Clinical exome sequencing of 1000 families with complex immune phenotypes: Toward comprehensive genomic evaluations. J Allergy Clin Immunol. 2022 Oct;150(4):947-954. doi: 10.1016/j.jaci.2022.06.009. Epub 2022 Jun 24. PubMed 35753512 ↗

Individual participant data

Plan to share: Undecided — The PI is on maternity leave and will discuss when they return

09

Timeline

8 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Jul 2042, 299 months after the start.

Of 50 observational studies under Primary Immunodeficiency Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 30. This study's planned 299 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2029 → Jul 2042 and completion Dec 2029 → Jul 2042.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2017
First posted
Jul 2, 2017
StartActual
Jul 31, 2017
Primary completionEst.
Jul 1, 2042was Dec 2029
CompletionEst.
Jul 1, 2042was Dec 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2029→Jul 1, 2042
Oct 26, 2026
Study completion
Dec 31, 2029→Jul 1, 2042
Oct 26, 2026
Eligibility
1 inclusion criterion edited; 2 criteria removed
What changed in the criteria
  • RemovedPARTICIPANT INCLUSION CRITERIA:
  • RemovedPARTICIPANT EXCLUSION CRITERIA:
Inclusion criteria
  • EditedProband participants: must be individuals under investigation by another NIH protocol on which they are co-enrolled, or are referred from the GDMCC protocol "Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults" (NCT04702243) or "Use of Tiered Genetic Sequencing and Specialty Referral for Identifying and Managing Rare Genetic Causes of Chronic Suppurative Respiratory Disease" (External study #: 26-1761). Probands may have a disease under investigation or be healthy volunteers.
Oct 22, 2026
Show all 8 updates
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: verification date
  2. Nov 2, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 27, 2026
    Minor edits only
    + 1 other change: verification date
  4. Oct 26, 2026
    Primary completion Dec 31, 2029→Jul 1, 2042
    Study completion Dec 31, 2029→Jul 1, 2042
    + 1 other change: verification date
  5. Oct 23, 2026
    Minor edits only
    + 1 other change: description
  6. Oct 22, 2026
    Eligibility 1 inclusion criterion edited; 2 criteria removed
    What changed in the criteria
    • RemovedPARTICIPANT INCLUSION CRITERIA:
    • RemovedPARTICIPANT EXCLUSION CRITERIA:
    Inclusion criteria
    • EditedProband participants: must be individuals under investigation by another NIH protocol on which they are co-enrolled, or are referred from the GDMCC protocol "Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults" (NCT04702243) or "Use of Tiered Genetic Sequencing and Specialty Referral for Identifying and Managing Rare Genetic Causes of Chronic Suppurative Respiratory Disease" (External study #: 26-1761). Probands may have a disease under investigation or be healthy volunteers.
  7. Oct 2, 2026
    Minor edits only
    + 1 other change: description
  8. Sep 28, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03206099
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Jul 31, 2017
Primary completion
Jul 1, 2042 (estimated)
Completion
Jul 1, 2042 (estimated)
Last update
Nov 17, 2026

Study contacts

Morgan N Similuk
Contact
morgan.similuk@nih.gov
(301) 435-6691
Morgan N Similuk
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion